Heatwurx (NASDAQ:PCSA) Announces Earnings Results

Heatwurx (NASDAQ:PCSA – Get Free Report) posted its earnings results on Friday. The company reported ($61.58) EPS for the quarter, missing the consensus estimate of ($1.00) by ($60.58), FiscalAI reports.

Heatwurx Trading Up 1.1%

PCSA traded up $0.02 during trading on Friday, reaching $1.86. 18,736 shares of the company’s stock were exchanged, compared to its average volume of 26,385. Heatwurx has a one year low of $1.04 and a one year high of $8.88. The firm has a fifty day moving average price of $1.81 and a two-hundred day moving average price of $2.30. The stock has a market capitalization of $5.21 million, a PE ratio of -0.44 and a beta of 1.24.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Heatwurx in a research note on Thursday, October 15th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

View Our Latest Stock Report on Heatwurx

Heatwurx Company Profile

(Get Free Report)

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.

Read More

Earnings History for Heatwurx (NASDAQ:PCSA)

Receive News & Ratings for Heatwurx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heatwurx and related companies with MarketBeat.com's FREE daily email newsletter.